What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.”In the company’s words, NCT04838444 on ClinicalTrials.gov
- Tested for
- Chikungunya Virus Infection
- Main trialPhase 3
- “In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).”In the company’s words, NCT04838444 on ClinicalTrials.gov
Other drugs for Chikungunya Virus Infection
- CHIKV VLP vaccineBavarian Nordic · Phase 3
- BBV87 Chikungunya vaccineBharat Biotech International Limited · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 3 Mar 2023 | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) | |
| Phase 3Completed | 19 May 2021 | Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults | |
| Phase 3Completed | 22 Jul 2021 | Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults | |
| Phase 3Withdrawn | 27 Aug 2024 | A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) | |
| Phase 3Withdrawn | Dec 2026 | A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children | |
| Phase 2Completed | 31 Jul 2024 | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026